What Researchers Did
This study identified predictors of high-grade late hematochezia following 5-fraction gantry-based stereotactic ablative radiation therapy (SABR) in 258 prostate cancer patients.
What They Found
High-grade late hematochezia (HH) was observed in 19.4% of patients, with grade 3 or higher toxicity in 3.1%. The median time to develop HH was 11.7 months, and at 2 years, cumulative HH ranged from 4.9% to 42.1% depending on the radiation dose and planning target volume margin. The volume of rectum receiving a radiation dose of 38 Gy (V38) was identified as a strong predictor of HH.
What This Means for Canadian Patients
Canadian prostate cancer patients undergoing SABR may experience late rectal bleeding, and understanding predictive factors can help clinicians tailor treatment plans to minimize this risk. This research could lead to improved patient counseling and potentially modified radiation delivery techniques to enhance safety and quality of life.
Canadian Relevance
This study was conducted by Canadian researchers, contributing to the body of knowledge for prostate cancer treatment within Canada.
Study Limitations
The findings are based on a specific treatment protocol and patient cohort from sequential phase 2 prospective trials, which may limit their generalizability.